Turn Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on September 30, 2025, the date the Securities and Exchange Commission declared effective Turn Therapeutics Inc.'s Registration Statement on Form S-1. The filing documents the Company's Direct Listing of its common stock on the Nasdaq Global Market. Turn Therapeutics Inc. is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing events; it does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing notes that registered stockholders may offer and sell up to 17,868,760 shares of Common Stock in connection with the Direct Listing.
Material Changes and Corporate Actions
- Direct Listing: The Company's common stock began trading on the Nasdaq Global Market effective September 30, 2025.
- Material Agreements: The Company entered into a Stockholders Agreement and a Registration Rights Agreement with founder/CEO Bradley Burnam and BEB Holdings, LLC. These agreements require holder consent for certain corporate actions and grant registration rights.
- Employment Agreements: New employment agreements were executed with CEO Bradley Burnam and Zuraiz Chaudhary.
- Board Appointments: Arthur Golden and Dr. Kent Kester were appointed as independent directors. Mr. Golden chairs the Compensation Committee and serves on the Audit and Nominating committees. Dr. Kester serves on the Audit and Compensation committees.
- Governance Documents: The Company filed an Amended and Restated Certificate of Incorporation and Bylaws, effective upon the Direct Listing.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the standard disclosures incorporated by reference from the Registration Statement. The primary focus is the execution of the Direct Listing and the establishment of post-listing governance structures.
Key Facts for Investor Verification
- Verify the trading symbol and initial trading price of Turn Therapeutics Inc. on the Nasdaq Global Market.
- Review the full text of the Stockholders Agreement (Exhibit 10.1) to understand restrictions on corporate actions requiring founder consent.
- Confirm the total number of shares outstanding and the specific number of shares available for sale by registered stockholders (up to 17,868,760).
- Examine the Amended and Restated Certificate of Incorporation (Exhibit 3.1) for any anti-takeover provisions or unique capital structure details.
- Check the Registration Statement (File No. 333-289972) for detailed financial history and risk factors not included in this 8-K.